CQUIRED APLASTIC anemia (AA) is characterized by peripheral blood pancytopenia and bone marrow hypocellularity. Although exact mechanisms responsible for its pathogenesis are unknown, possible mechanisms include a primary stem cell defect, immune-mediated inhibition of hematopoiesis or an abnormal bone marrow microenvironment.'.' Several studies have used bioassays to demonstrate elevated serum concentrations of colony-stimulating activity (CSA) in patients with A A . 3 -6 The bioassays detect the stimulating activity of various hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and other, only partially defined factors with burst promoting activity.
G-CSF is a lineage-specific hematopoietic growth factor that stimulates the proliferation and differentiation of neutrophil precursors. G-CSF activates several functions of mature neutrophils, including mobility, adherence, phagocytosis, bacterial killing, and superoxide Monocytdmacrophages and bone marrow stromal cells are known to produce G-CSF. ' In recent clinical trials using recombinant human (rh) G-CSF for treatment of AA, a transient increase in neutrophil counts was induced in the majority of patients.'.'' Despite the widespread use of rhG-CSF in the treatment of AA, there are few studies that examine endogenous concentrations of G-CSF in patients with AA. Watari et al" have reported serum concentrations of G-CSF in 11 patients with AA using an enzyme immunoassay (ELISA). Because the assay had a lowsensitivity, the serum G-CSF concentrations were below the limit of detection in some of the AA patients and most of the normal healthy subjects. The recent development of a highly sensitive chemiluminescent immunoassay (CLEIA) has improved the ability to detect low levels of G-CSF. I2 We used a CLEIA to investigate the endgenous concentrations of plasma G-CSF at diagnosis and during follow-up in a series of 68 patients with AA. We also studied the predictive value of plasma G-CSF concentrations in determining immunosuppressive (IS) therapy for AA, signs of infection. Although a decrease in the plasma G-CSF concentration was observed in all patients who achieved self-sustaining hematopoiesis following bone marrow transplantation (BMT) or immunosuppressive (IS) therapy, it was lower in patients undergoing BMT as compared with those receiving IS therapy for any given degree of neutropenia. Plasma G-CSF concentrations were higher in patients responding to IS therapy than in nonresponders. This study demonstrated the negative feedback regulation of G-CSF via ANC in AA patients. In addition, our results suggested that plasma G-CSF concentrations may be useful in predicting the clinical response to IS therapy. 0 7996 by The American Society of Hematology. marrow hypoplasia. The median age was 11 years with a range of 1 to 45 years. The duration from diagnosis to time of study ranged from 1 week to 168 months. Twenty-five patients were studied before the initiation of any specific therapy for AA. Thirty-five patients had received anabolic steroids, corticosteroids or both, and eight had received antilymphocyte globulin (ALG) or cyclosporine before sample collection. None of the patients had responded to these therapies at the time of sampling. Fifteen patients were taking corticosteroids, six anabolic steroids, three corticosteroids and anabolic steroids and two corticosteroids and cyclosporine, but no patients were receiving exogenous rhG-CSF at the time of sampling.
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MATERIALS AND METHODS
Patients. Patient characteristics are listed in
Thirty-eight patients were treated with IS therapy following sample collection. Twenty-four patients received a combination of ALG (Ahlbulin, Green Cross, Osaka, Japan, 15 patients; Lymphoser, Swiss Vaccine Institute, Berne, Switzerland, 16 patients) and highdose methylprednisolone with anabolic steroids. ALG was administered daily at a dose of 40 mg/kg/day intravenously for 5 days. Seven patients were treated with a combination of ALG (Lymphoglobulin, MBrieux, Lyon, France), cyclosporine, methylprednisolone and anabolic steroids. ALG was infused at a dose of 0.75 mL/kg/day intrave- For personal use only. on August 30, 2017. by guest www.bloodjournal.org From nously for 5 days. Cyclosporine was given orally at a dose of 6 mg/ kg/day for 6 months with dose adjustment according to blood levels. The hematologic response of each patient was evaluated 3 months after the initiation of treatment. Responders were defined as those patients with an increase in at least two of the following peripheral blood parameters: neutrophils >1.0 X lo9& platelets >50 X lo9/ L, and reticulocytes >60 X 109/L. Twenty-five patients received bone marrow transplantation (BMT) following sample collection. A repeat sampling was performed 2 to 3 months following IS therapy in 10 patients and following BMT in 13 patients.
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Infection was presumed in a clinically symptomatic patient and whenever one of the following criteria was fulfilled: positive Creactive protein or fever higher than 38°C in three successive readings that was not related to the transfusion of blood products. Patients were informed that blood samples were obtained for research purposes and that their privacy was protected. We also measured the plasma G-CSF concentrations in 12 healty subjects. Their median age was 9 years with a range of 3 to 40 years.
Methods. Venous blood was collected using an anticoagulant, and plasma was separated by centrifugation and stored at -80°C until thawed for assay. Plasma G-CSF concentrations were determined by a CLEIA as described by Kiriyama et al.'* Briefly, 100 pL of each sample or the standard rhG-CSF solutions (Chugai Pharmaceutical CO, Tokyo, Japan), together with 250 pL of 0.01 m o m phosphate buffer containing 0.2% bovine serum albumin (Intergen, New York, NY), 0.1% Tween 20, 10 mmol/L EDTA, 0.5 m o m NaCI, and 0.1% NaN3, were added to glass tubes. Anti-G-CSF IgG coated polystyrene beads (Precision, Chicago, IL) were then added. Antiserum against human G-CSF was obtained from goats immunized with the purified rhG-CSF. Tubes were incubated in a water bath for 4 hours at 37°C with continuous shaking. Following incubation, the beads were washed three times with saline containing 0.05% Tween 20 and incubated (1 hour, 37°C) with 350 pL of IgG solution labelled with glucose oxidase (Toyobo, Osaka, Japan). After washing three times as above, the beads were transferred to a new polypropylene tube containing 300 pL of 0.1 m o m glucose substrate solution in 10 mmol/L sodium acetate (pH 5.1). After an overnight incubation at room temperature, the tubes were set in a luminometer (Leader-1, Gen-Probe, San Diego, CA). They were automatically filled with 200 pL of 50 nmol/L luminol and 200 pL of 10 mmoVL potassium ferricyanide solutions. The chemiluminescent light emission was measured for 10 seconds. The lower limit of sensitivity of this assay is 0.5 pg/mL..
Statistical analysis was performed with FISHER software (Nakayama CO, Tokyo, Japan). Pearson's test was used for calculating correlation coefficients. The series of patients were compared with the nonparametric Wilcoxon two-tailed test and chi-squared test. A P value of less than .OS was considered significant.
RESULTS
Plasma G-CSF concentrations in AA patients and normal healthy controls were determined (Table 1, Fig 1) . In 51 AA patients without signs of infection, plasma G-CSF concentrations were significantly elevated compared with the normal control group (mean plasma G-CSF, 42.1 ? 23.6 pg/mL v 6.8 It 1.7 pg/mL, P < .001). Plasma G-CSF concentrations were also significantly higher in 17 AA patients with signs of infection as compared with the 51 AA patients without obvious infection (mean plasma G-CSF, 1211.8 ? 1850.4 p@mL v 42.1 ? 23.6 pg/mL, P < .01). The highest concentration of plasma G-CSF was observed in a patient with bacteremia due to Klebsiella pneumonia.
The relationship between plasma G-CSF concentrations and absolute neutrophil count (ANC) in 5 1 AA patients without signs of infection was examined (Fig 2) . There were variations in the results, but a significant negative correlation was seen overall (r = -0.50, P < ,001). The 51 patients were divided into groups on the basis of sex, age, interval between diagnosis and time of study entry, or the type of therapy at the time of study entry. None of these variables were significantly associated with the differences in mean plasma G-CSF concentrations between subgroups.
The lines for regression of plasma G-CSF concentrations on ANC were plotted for individual patients following BMT or IS therapy (Fig 3) . Plasma G-CSF concentrations were determined before and 2 to 3 months after therapy. In the 13 patients undergoing BMT, the mean ANC increased from 0.77 -C 0.48 X 10y/L to 1.98 It 1.04 X 10y/L following BMT.
The mean ANC also increased from 0.50 0.23 X l O Y L to 1.64 -t 1.20 X lo9& in 10 responders to IS therapy. Although a decrease in the plasma G-CSF concentration was observed in all patients who achieved self-sustaining hematopoiesis after treatments, it was more prominent in the patients undergoing BMT as compared with patients receiving IS therapy. Although the mean ANC was not significantly different between the two groups, the mean plasma G-CSF concentration was significantly lower in the patients undergoing BMT than in responders to IS therapy (8.3 t 4.9 pg/mL v 21.3 2 11.1 pg/mL, P < .001). Plasma G-CSF concentrations were less than 10 pg/mL in eight of 13 patients undergoing BMT, while only one of 10 patients showed a decline of plasma G-CSF below 10 pg/mL after IS therapy ( P < .05).
We compared the pretreatment plasma G-CSF concentrations between the responders and nonresponders to IS therapy. Although the percentage of the patients with ANC less than 0.5 X 109/L was not significantly different between two groups, the mean plasma G-CSF concentration of 11 responders was significantly higher than that of 12 nonresponders (69 2 26 pg/mL. v 29 -C 12 pg/mL, P < .001).
Because a negative correlation between ANC and plasma G-CSF concentrations was observed, we plotted the individual G-CSF concentration of both groups. Nine of 1 l responders had pretreatment G-CSF concentrations that were higher than values estimated from the regression lines for 51 AA patients without signs of infection (Fig 4) . In contrast, the plasma G-CSF concentrations were below the regression line in 1 I of 12 nonresponders.
DISCUSSION
We measured endogenous plasma G-CSF concentrations in 68 patients with acquired AA by a highly sensitive CLEIA. It had been reported earlier that CSA is elevated in the sera of patients with However, these studies employed bioassays for the measurement of CSA and, therefore, detected the combined stimulatory effects of various hematopoietic growth factors, such as G-CSF and GM-CSF.
Serum G-CSF concentrations have been measured by enzyme immun~assay,'~.'~ radioimmunoas~ay,'~ or a bioassayI6 using a G-CSF-dependent cell line. Because the lower limits of detection for these assays were between 30 and 50 pg/ m L , they are not sensitive enough to detect the serum concentrations of G-CSF in a considerable percentage of AA patients or healthy subjects. The CLEIA is highly sensitive and can detect as little as 0.5 pg/mL of G-CSF. Consequently, it is possible with this assay to determine the G-CSF concentrations in healthy controls and patients with disease in which decreased production of G-CSF is suspected.
There are a few small studies that have examined serum G-CSF concentrations in patients with AA. Watari et al" used an enzyme immunoassay to report the serum G-CSF concentrations in 11 patients with AA. In their report, nine of the 11 patients had G-CSF concentrations greater than the lower limit of detection (mean, 260 pg/mL). Interestingly, they found a negative correlation between G-CSF concentrations and ANC. Omori et a l l 7 also reported that three of six patients with AA had G-CSF concentartions greater than 200
In agreement with previous studies, we found a significantly higher concentration of plasma G-CSF in AA patients than in healthy controls. We also found that plasma G-CSF concentrations were significantly higher in AA patients with PdmL.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From signs of infection than in those without. However, the mean G-CSF concentration in AA patients without signs of infection was considerably lower in our study than previously reported. The reasons for this difference are uncertain. Because previous reports did not refer to the presence of infections, this aspect requires further clarification. High endogenous serum G-CSF concentrations were also observed in patients with other kinds of neutropenia, such as severe congenital neutropenia," cyclic neutropenia," and neutropenia secondary to high-dose chemotherapy." We clearly demonstrated an inverse relationship between G-CSF concentration and ANC in patients with AA. The increased G-CSF concentrations could be explained by upregulation of G-CSF production due to a feedback mechanism induced by a lack of neutrophils. We previously reported the increased ability of bone marrow stromal cells to release G-CSF in response to interleukin-l in patients with AA." Because mature neutrophils bind G-CSF and can potentially act as a clearance mechanism, another possibility is decreased G-CSF clearance due to the deficiency of peripheral neutrophils. Several studies have demonstrated that rhG-CSF pharmacokinetics do not remain constant and that G-CSF disposition is influenced by ANC.2',22 Higher serum concentrations, slower clearances, and longer half-lives of G-CSF are associated with a low-ANC. When we measured the plasma G-CSF concentrations during rhG-CSF therapy in some patients with AA, decreases in G-CSF concentrations were observed as the ANC increased during therapy.
In all AA patients with signs of infection, the G-CSF concentrations increased in the acute phase. Especially noteworthy were G-CSF concentration increases to very high levels of 3,500 and 6,000 pg/mL, respectively in two patients who suffered from documented bacterial infections. In patients with bacterial infection, the release of G-CSF from the monocyte/macrophage or bone marrow stromal cells may be increased in response to inflammatory mediators such as endotoxin, tumor necrosis factor-a, and interleukin-1 . 23 Because peripheral monocytes were totally absent in the two patients, bone marrow stromal cells may be more important as the source of G-CSF in these patients.
We studied the sequential changes in plasma G-CSF concentration in patients who demonstrated an increase in their ANC following IS therapy or BMT. A decrease in plasma G-CSF concentrations was observed in all patients who achieved self-sustaining hematopoiesis after treatment. These findings support the hypothesized feedback mechanism for release of G-CSF in patients with AA. For any given degree of neutropenia, the plasma G-CSF concentrations were lower in patients undergoing BMT than in patients receiving IS therapy. The damage to G-CSF producing cells, such as bone marrow stromal cells, by conditioning regimens or drugs for the prophylaxis of graft-versus-host disease may be responsible for decreased production of G-CSF in patients undergoing allogeneic BMT.
Currently, IS therapy with ALG is widely used for patients with AA."-27 Because the clinical response rate and therapeutic outcome for individual patients to IS therapy varies, an in vitro test identifying potential responders would be desirable. The predictive value of CSA forithe response to IS therapy has been discussed in several Nissen et a15 suggested that elevated serum concentrations of CSA in patients with AA resulted from an immunologic reaction, and that these patients were more likely to respond IS therapy. Recently, Schrezenmeier et also found that serum GM-CSF concentrations measured by enzyme immunoassay were significantly higher in patients responding to IS therapy as compared with nonresposnding patients. The median serum GM-CSF concentrations of responders and nonresponders were 58.5 pg/mL and 16.0 pg/mL, respectively. They also suggested that elevated GM-CSF concentrations were an indicator of T-cell activation and might, on that basis, predict a response to a T lymphocyte targeted treatment.
We found that the mean plasma G-CSF concentrations of responders to IS therapy was sigmficantly higher than nomsponden. Nine of 11 responden had ptreatment GCSF concentrations higher than values estimated fmm the repssion lines for 51 AA patients. In conhast, 11 of 12 nonresponden had pretreatment G-CSF concentrations lower than the repssion line. The reason why the plasma G-CSF concentration correlates with the response to IS therapy is unclear. Unlike GM-CSF, an elevated plasma G-CSF concentration dose not imply T-cell activation because T lymphocytes do not produce G-CSF. Stem cell factor (SCF) is a newly identified hematopoietic p w t h factor that acts as a ligand for the c-kit receptor.31-33 It is produced mainly by bone marrow stromal cells, as is G-CSF?2.33 Filipwicz et ds4 have reported that serum concentrations of SCF in AA patients were in the low-range of control serum levels determined in healthy subjects, and high-SCF serum concentrations were associated with a rapid recovery of hematopoietic function after treatment. Elevated G-CSF and SCF concentrations may reflect the optimal hematopoietic microenvhnment and favor the response to IS therapy.
In summary, our results demonstrated negative feedback regulation between plasma G-CSF concentrations and ANC in patients with AA. Measurement of pretreatment plasma G-CSF may be useful in predicting the response to IS therapy for patients with AA.
